Related Experiment Video

Updated: Nov 2, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Ruxolitinib for refractory large granular lymphocyte leukemia

Aline Moignet1, Cédric Pastoret2,3, Guillaume Cartron4

  • 1Centre Hospitalier Universitaire de Rennes, Service d'Hématologie Clinique, Rennes, France.

American Journal of Hematology
|June 16, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.7K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K

Related Experiment Videos

Last Updated: Nov 2, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.7K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.

European journal of nuclear medicine and molecular imaging·2026

Hypnosis associated with local anesthesia versus local anesthesia alone during bone marrow biopsy: a randomized, controlled, multicenter study, QUALHYBOM.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

Nature medicine·2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Blood·2026

Pharmacodynamics of Caplacizumab in Healthy Volunteers and Phase 2/3 Trial Patients with Immune-mediated Thrombotic Thrombocytopenic Purpura.

Thrombosis and haemostasis·2026

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care.

American journal of hematology·2026

Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study.

American journal of hematology·2026

2026 Update on Clinical Trials in β-Thalassemia.

American journal of hematology·2026

Monoclonal Gammopathy of Thrombotic Significance.

American journal of hematology·2026

Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations.

American journal of hematology·2026

Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis.

American journal of hematology·2026

Regulatory T cells: From Foxp3 to tolerance-inducing therapies.

The Journal of investigative dermatology·2026

Prospective Evaluation of Ustekinumab Dose Intensification in Inflammatory Bowel Diseases.

Gastro hep advances·2026

Does imepitoin reduce signs of fear and anxiety in dogs frightened by loud noises?

Veterinary evidence·2026

Immunophenotyping, activation, and expansion of gamma delta T cells: flow cytometry profiling and ex vivo manipulation strategies.

Frontiers in immunology·2026

Correlation between the CD8+ T cell/IFN-γ axis and clinical disease progression at different phases of ITP.

Frontiers in pediatrics·2026

Clinical analysis of laparoscopic transabdominal preperitoneal hernioplasty (TAPP) for incarcerated inguinal hernia.

Medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us